Clinical trials are under way for a candidate vaccine for Lassa fever at the University of Maryland School of Medicine, sponsored by NIH’s National Institute of Allergy and Infectious Diseases. The LASSARAB vaccine, using an inactivated rabies virus has already been shown to protect animals from lethal doses of Lassa virus. The disease, spread by rodents and person-to-person contact, often results in severe illness and permanent hearing loss. There are currently no specific treatments for Lassa fever.
News – Lehigh Valley Health Network to pay $65 million in landmark ransomware settlement – TEISS
Lehigh Valley Health Network will pay a landmark $65 million in a settlement in a ransomware case. This will be the largest sum ever paid
